Monthly Archives May 2019

Please refer to the original article published 30 April 2019. Supply of the above mention product is expected to be exhausted in the next couple of weeks. The alternative will be available late May early June 2019. Pharmacode 2565773     Clomipramine-Apo Tab 25 mg 50                      Schedule price $4.73 ProPharma /PWR will implement automatic replacement as existing stocks are exhausted, meaning…

PHARMAC announced 11 April 2019 that Lamotrigine was to move to one funded brand effective 1 October 2019. This will provide an opportunity for pharmacy to provide / offer patients the opportunity to remain on their existing medication (Lamictal). Click here to read the notification from the supplier GSK. ProPharma / PWR have prepared an analysis (based on OP Dispensing)…

Click here to read the notification from Pfizer relating to the above mentioned products. As stated this is from a range of projected dates. Keep in mind that traditionally, delisting from the Pharmaceutical Schedule and HML occurs approximately 6 months after discontinuation, but can vary. There are limited supplies within the supply chain at wholesale level and following depletion of…

The supplier has advised of a potential supply issue of the above mentioned product. To ensure continuity of supply, PHARMAC will list & fully fund an alternative product under Section 29. Pharmacode 2567989                 Methyldopa Mylan Tab 250 mg 500 S29           Schedule price $52.85 ProPharma / PWR will not be able to implement replacement due to the alternative product being…

The supply of Acarbose Tablets has been disrupted since October 2018, when Bayer advised of issues with the supply of Glucobay Tablets. Acarbose supply issue is not resolved.  Effective from 1 June 2019 there will be new listing of a registered product in the Pharmaceutical Schedule. Accarb Mylan Tab 100 mg 90                Pharmacode 2402416                   Schedule price $20.23 However…

Click here to read the Novartis New Zealand Limited notification relating to the above mentioned product. You must immediately complete and fax the acknowledgement form provided regardless of whether you have stock or not. This is a requirement under your current ICPSA 2018. NOTE: ProPharma /PWR will be processing credit returns and all credit returns must be accompanied by a…

Hi all GSK Supply Update Information | 12 March 2019 Please find attached details on Price Support Changes for the below products: Please review the below Supply Update: If you have any questions or would like further information on any GSK product please do not hesitate to contact myself, Quincy Liu or the GSK Customer Services team – Phone: 0800…

This update from the article published earlier stating it is a full recall (18 April 2019) simply extended the time for returning stock to your wholesaler from 17 May 2019 to 30 June 2019. Click here to read the updated WELEDA notification relating to the above mentioned product. All batches are now on recall. Click here to access the updated…

The supply issue was originally disrupted October 2018 and has been on-going since then. ProPharma / PWR have managed this supply issue extremely well and have at all times been able to supply product to meet the needs of all our customers. An excellent achievement. Effective immediately we will be removing the allocation on both of the following Paracetamol presentations:-…

Close